NuPathe to Present at Biotech Showcase 2012
(firmenpresse) - CONSHOHOCKEN, PA -- (Marketwire) -- 01/04/12 -- NuPathe Inc. (NASDAQ: PATH), an emerging biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that , chief executive officer, will present a company overview at Biotech Showcase 2012 on Wednesday, January 11, 2012, at 2:00 p.m. EST. The conference is being held at the Parc 55 Wyndham Hotel in San Francisco, CA.
A live audio webcast of the presentation will be available via the "Investor Relations" page of the NuPathe website, . Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on NuPathe's website for 90 days following the presentation.
Inc. () is an emerging biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, , is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates in preclinical development: for the continuous symptomatic treatment of Parkinson's disease, which the company plans to partner, and for the long-term treatment of schizophrenia and bipolar disorder.
John Woolford
Westwicke Partners, LLC
(443) 213-0506
Keith A. Goldan
Vice President & Chief Financial Officer
NuPathe Inc.
(484) 567-0130
Tiberend Strategic Advisors, Inc.
Jason Rando
212-827-0020
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.01.2012 - 15:20 Uhr
Sprache: Deutsch
News-ID 1070050
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
CONSHOHOCKEN, PA
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 103 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NuPathe to Present at Biotech Showcase 2012
"
steht unter der journalistisch-redaktionellen Verantwortung von
NuPathe Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
